Advertisement

Picture Sino Biological Symposium Antibody Engineering Leipzig 650x100px
Document › Details

AstraZeneca plc. (11/9/23). "Press Release: AstraZeneca Licenses Novel Agent for the Treatment of Cardiometabolic Conditions and Obesity [This press release is intended for investors and business / science media]".

Region Region ALL
Organisations Organisation AstraZeneca plc (LSE: AZN)
  Group AstraZeneca (Group)
  Organisation 2 Eccogene (CN)
Products Product ECC5005 (Eccogene / AstraZeneca)
  Product 2 obesity drug
Index term Index term AstraZeneca–Eccogene: GLP-1 receptor agonist, 202311– license ww excl $185m upfront + $1.825b milestones + royalties for ECC5004
Persons Person Barr, Sharon (AstraZeneca 202311 EVP BioPharmaceuticals RnD)
  Person 2 Zhou, Jingye (Eccogene 202311 CEO + Co-Founder before Lilly + GSK + Tetraphase Pharmaceutical)
     


   
Record changed: 2024-03-14

Advertisement

Picture Sino Biological Symposium Antibody Engineering Leipzig 650x200px

More documents for AstraZeneca (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Voices Martin Rahmel TU Berlin GreenChem 650x300px




» top